Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1 by the USA Food and Drug Administration
Authors:ID Mountzios, Giannis (Author)
ID Remon, J. (Author)
ID Novello, Silvia (Author)
ID Blais, N. (Author)
ID Califano, R. (Author)
ID Čufer, Tanja (Author)
ID Dingemans, Anne-Marie C. (Author)
ID Liu, S. V. (Author)
ID Peled, N. (Author)
ID Pennell, N. A. (Author)
Files:.pdf PDF - Presentation file, download (106,29 KB)
MD5: 0E9697A221FB531E45F7409FE050F7AE
 
URL URL - Source URL, visit https://academic.oup.com/annonc/article-abstract/30/11/1686/5559466?redirectedFrom=fulltext
 
Language:English
Typology:1.03 - Other scientific articles
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Keywords:non-small cell lung carcinoma, drug therapy, KEYNOTE-024 trial, pemrolizumab, treatment
Publication status:Published
Publication version:Version of Record
Place of publishing:Velika Britanija
Publisher:Elsevier
Year of publishing:2019
Number of pages:str. 1686-1688
Numbering:Vol. 30, iss. 11
PID:20.500.12556/DiRROS-12422 New window
UDC:616.2
ISSN on article:1569-8041
DOI:10.1093/annonc/mdz295 New window
COBISS.SI-ID:2048615281 New window
Copyright:© 2019 THE AUTHORS
Note:Nasl. z nasl. zaslona; Soavtorica iz Slovenije: T. Cufer; Opis vira z dne 15. 1. 2020;
Publication date in DiRROS:21.09.2020
Views:1596
Downloads:1068
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Annals of oncology
Publisher:Elsevier
ISSN:1569-8041
COBISS.SI-ID:3151892 New window

Licences

License:CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Licensing start date:03.09.2019

Secondary language

Language:Undetermined
Keywords:nedrobnocelični karcinom pljuč, terapija z zdravili, raziskava KEYNOTE-024, pemrolizumab, zdravljenje


Archive

niGradiv

Back